Clinical manufacturing of CAR T cells: Foundation of a promising therapy Journal Article
| Authors: | Wang, X.; Rivière, I. |
| Article Title: | Clinical manufacturing of CAR T cells: Foundation of a promising therapy |
| Abstract: | The treatment of cancer patients with autologous T cells expressing a chimeric antigen receptor (CAR) is one of the most promising adoptive cellular therapy approaches. Reproducible manufacturing of high-quality, clinical-grade CAR-T cell products is a prerequisite for the wide application of this technology. Product quality needs to be built-in within every step of the manufacturing process. We summarize herein the requirements and logistics to be considered, as well as the state of the art manufacturing platforms available. CAR-T cell therapy may be on the verge of becoming standard of care for a few clinical indications. Yet, many challenges pertaining to manufacturing standardization and product characterization remain to be overcome in order to achieve broad usage and eventual commercialization of this therapeutic modality. |
| Keywords: | review; cancer patient; t lymphocyte; carcinoembryonic antigen; epidermal growth factor receptor; epidermal growth factor receptor 2; cd20 antigen; t lymphocyte receptor; cryopreservation; dna modification; messenger rna; chimeric antigen receptor; cell therapy; antigen presenting cell; t lymphocyte activation; bioreactor; complementary dna; cd33 antigen; mesothelin; cd30 antigen; personalized medicine; cd22 antigen; natural killer cell receptor nkg2d; glypican 3; human; priority journal |
| Journal Title: | Molecular Therapy - Oncolytics |
| Volume: | 3 |
| ISSN: | 2372-7705 |
| Publisher: | Cell Press |
| Date Published: | 2016-01-01 |
| Start Page: | 16015 |
| Language: | English |
| DOI: | 10.1038/mto.2016.15 |
| PROVIDER: | scopus |
| PMCID: | PMC4909095 |
| PUBMED: | 27347557 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 3 January 2017 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work